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Abstract
Background: Atherosclerosis is a common pathological basis of cardiovascular disease. Adiponectin (APN) has been
shown to have an anti-atherosclerosis effect, and the underlying mechanisms, however, are largely unknown.
Nuclear factor κB (NF-κB) has also been regarded as a proatherogenic factor, mainly because of its regulation of a
variety of the proinflammatory genes linked to atherosclerosis. It was hypothesized that the inhibitory effects of
adiponectin on the atherosclerosis is through the inhibition of NF-κB signaling pathway.
Methods: We injected adenovirus of Ad-eGFP virus (control group) or the same amount of Ad-APN-eGFP virus
(APN group) in ApoE-/- mice tail-intravenously. Blood samples and aorta were executed at 0 day, 4, and 8 week of
high-fat diet feeding. Histopathological changes of aortic arch root were detected. Levels of TC, TG, HDL-C, LDL-C
were measured. Adiponectin and Matrix metalloproteinases-9 (MMP-9) concentration were detected by enzyme-
linked immunosorbent assay. Gene and protein levels of adiponectin, eNOS, IL-6, MCP-1,VCAM-1, and other
inflammatory factors were determined. Adiponectin, NF-κB p65 in aortic arch root were determined by
immunofluorescence and western blot.
Results: Transduction of Ad-APN inhibited the formation of atherosclerotic plaque in aorta when compared with
control group. The lesion formation in aortic arch root was inhibited significantly (P < 0.01). Lesion lumen ratio
decreased significantly (P < 0.001). The expression of adiponectin attenuated the increases of serum TC (P < 0.001),
TG (P < 0.001), and LDL-C (P < 0.001) induced by the high-fat diet, and the increase in body weight (P < 0.05). As
increasing serum adiponectin, the levels of MMP-9 were significantly decreased (P < 0.05). The exogenous
adiponectin increased the gene expression of the anti-inflammatory factors eNOS (P < 0.05) and IL-10 (P < 0.001),
and reduced the gene expression of inflammatory factors tumor necrosis factor-α (TNF-α) (P < 0.001), IL-6 (P < 0.001),
VCAM-1 (P < 0.05), respectively. Adiponectin effectively inhibited the activation of NF-κB pathway and the
expression of NF-κB nuclear protein p65.
Conclusions: Adiponectin may protect the aorta from atherosclerotic injury by reducing inflammation. The
molecular mechanism may involve inhibited the expression of downstream components of NF-κB and its
transcription factors.
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Background
Cardiovascular disease is one of the leading causes of
death worldwide [1]. Atherosclerosis is one important
cause of cardiovascular disease. Atherosclerosis is
characterised by the accumulation of lipid-laden mac-
rophages in atherosclerotic lesions and occurs prefer-
entially at arterial branching points, which are prone
to inflammation during hyperlipidaemic stress [2].
Inflammation mediates its effects on atherosclerosis
both through modulation of traditional risk factors
and by directly affecting the vessel wall. Treatments
such as TNF-α inhibitors might have a beneficial
effect on cardiovascular risk [3]. Further knowledge of the
predictors of cardiovascular risk, the effects of early con-
trol of inflammation and of drug-specific effects are likely
to improve the recognition and management of
cardiovascular risk in patients with atherosclerosis.
Adiponectin, also referred to as ACRP30 (adipocyte
complement-related 30 kDa protein), is an specific
adipokine secreted by adipose tissue [4]. Adiponectin
exerts its biological effects via binding to two struc-
turally and functionally distinct, G protein-coupled,
seven-transmembrane receptors, adiponectin receptors
1 and 2 (AdipoR1 and AdipoR2) [5]. Chronic inflam-
matory states in obesity, obesity-linked insulin resist-
ance, and diabetes are associated with reduced
expression of both adiponectin and its cell surface
receptors [6]. Clinical studies indicate a close associ-
ation between low plasma adiponectin levels and
atherosclerosis [7]. In addition, plasma levels of C-
reactive protein (CRP) and IL-6 levels are both nega-
tively correlated with plasma adiponectin levels [8]. In
vitro experiments showed that adiponectin reduces
the expression of class A scavenger receptor(SR-A) in
human monocyte-derived macrophages and prevents
macrophage foam cell formation. Adiponectin inhibits
endothelial synthesis of IL-8 in human aortic endo-
thelia cells stimulated with TNF-α [9]. Of importance,
ApoE-/-/APN-/- double-KO mice show accelerated
atherogenesis, accompanied by increased T lympho-
cyte accumulation in atherosclerotic lesions, compared
to ApoE-/- mice [10]. Also there were experiments
showed that the actions of adiponectin on the cardiovas-
cular system are complex and multifaceted, with a min-
imal direct impact on atherosclerotic plaque formation in
preclinical rodent models [11]. In this study, atheroscler-
osis mice model was established, intervented with the
adenovirus expressing mice adiponectin DNA(Ad-APN),
to investigate the effect of adiponectin prevention in
atherosclerosis. And investigate the effect of adiponectin
on the protein p65 in NF-κB signaling pathway and the
downstream of the inflammatory cytokines expression.
Laying the theoretical basis for treatment of atheroscler-
osis with adiponectin.
Methods
Mouse model of atherosclerosis
Male ApoE-/- mice aged 12 weeks were used in this
study as animal model of atherosclerosis. All procedures
related to the animal experiments were approved
(IACUC-20130709010) by the Animal Ethics Committee
of First Affiliated Hospital of Xinjiang Medical University.
High-fat diet (Jiangsu Medicine Co., Ltd. Nanjing, China)
containing 35 % fat, 45 % carbohydrates, and 1.25 % chol-
esterol. Adenovirus vector containing the gene for full
length mouse adiponectin was ordered from Shenzhen
Byrne Biotechnology Co., Ltd. 120 male ApoE-/- mice aged
12-week were randomly and evenly assigned into two
groups (60 mice per group), and were fed with a high-fat
diet to induce atherosclerosis. At 0 day, 2, 4, and 6 week
of high-fat diet feeding the 2 groups of mice were injected
tail-intravenously with either 100 μl (3.0 × 108 p.f.u) of
Ad-eGFP virus (control group) or the same amount of
Ad-APN-eGFP virus (APN group). Blood samples and
aortas tissues were harvested at 0 day, 4, and 8 week.
Pathological detection of vascular tissue
Aortas were carefully excised from mice and examined for
immunohistology and characterization of atherosclerotic
lesions. Each was then fixed with paraformaldehyde and
subjected to common dehydration to render the sample
transparent. After that, paraffin embedding was performed
and the samples were sliced. For the aortic root, Oil red O
staining was used to detect the surface lesion percentage;
Hematoxylin-eosin (HE) staining was used to detect the
pathological alterations; Masson staining was used to
evaluate the collagen content and fibrous cap thickness of
the plaque area; Immunohistochemical approach was used
to detect the overexpression of adiponectin, Immunohis-
tochemical approach was used to detect the proportion of
macrophages and smooth muscle cells; Analysis was
performed on the Image J to determine the area of
damage caused by atherosclerosis in the aorta and the
lesion rate of arterial lumen [12].
Measurement of blood parameters
A whole blood sample was held for 30 min at room
temperature to allow clotting. The sample was centri-
fuged at 3,000 g for 10 min at 4 °C. The serum was
transferred in separate tubes without disturbing blood
clots and stored at −80 °C [13]. Full automatic biochem-
ical analyzer (FABA) (HITACHI 7020) was used to assess
total cholesterol (TC), triglyceride (TG), high-density lipo-
protein cholesterol (HDL-C), and low-density lipoprotein
cholesterol (LDL-C). The double-antibody sandwich
enzyme-linked immunosorbent assay (ELISA) method
was used to determine the concentration of adiponectin
and MMP-9 in the serum. An enzyme-labeled instrument
(Bio-Rad Benchmark Plus), blood parameter measurement
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reagent (Roche Diagnostics (Shanghai) Ltd. Shanghai,
China), adiponectin ELISA kit (America Biomerica
Company) and MMP-9 ELISA kit (USA & Canada | R&D
Systems, Inc) were used in the experiments.
Determination of mRNA levels
Real-time fluorescence quantitative polymerase chain
reaction(qPCR) test was used to assess gene expression.
Total RNAs were extracted from the aorta of mice using
Trizol (Invitrogen, California, USA) according to the man-
ufacturer’s instructions. Then 1 μg DNase I-treated
(Thermo, USA) total RNA was reverse-transcribed using
Primer Script Strand cDNA Synthesis Kit (Promega,
USA). Reverse transcription and real-time fluorescent
quantization were performed according to the instructions
provided. PCR device (BIO-RAD My Cycler), electrophor-
esis apparatus trophoresis (Liuyi Brand DYY-6D) and high
speed freezing centrifugal (HC-3018R) were used. Samples
were run in triplicate. The housekeeping gene β-actin was
used for internal normalization. The mean SQ values of
the target gene primers were compared to those of β-actin
specific primers using the double standard curve method.
Data are presented as fold changes of transcripts for the
target gene normalized to β-actin compared with control
mice. Primers were designed to amplify mouse adiponec-
tin, eNOS, TNF-α, IL-6, VCAM-1, β-actin, IL-10. All
primers were obtained from Takara (Table 1). The reac-
tion was under the following reaction conditions: 35 cycles
of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. A
DNA purification kit was used (Tiangen Biotech Co., Ltd.,
China), cDNA was amplified using a QuantiFast SYBR®
Green Real-time PCR Master Mix (Qiagen, GER) in 96-
well optical reaction plates on an fluorescent quantization
PCR device (CFX96) according to the manufacturer’s
protocol. The cycling parameters were as follows: 95 °C
for 5 min and then 40 cycles of 95 °C for 10 s, 60 °C for
30 s, followed by a melting curve analysis.
Immunofluorescence staining
Immunofluorescence staining was used to identify NF-
κB p65 and adiponectin protein localization in sections
of aortic root. Paraffin-embedded aortic, sections were
incubated with 3 % H2O2, then for antigen repair and
closure [13]. Sections were then incubated overnight at
4 °C with a NF-κB p65 antibody (America Thermo
Fisher, 1:50, rabbit polyclonal), The sections were then
incubated with goat anti-rabbit lgG, dylight™ 594 (America
Thermo Fisher, 1:200, goat anti-rabbit IgG). Sections were
counter-stained with DAPI to identify nuclei before
mounting. Then counter-stained with confocal micros-
copy. The sections were used for sequential double
immunofluorescence staining. Primary antibody for
adiponectin (America Thermo Fisher, 1:250, mouse
momoclonal) and secondary antibody dylight™ 488
(America Thermo Fisher, 1;200, goat anti-mouse IgG),
von Willebrand factor (vWF; endothelial cell marker,
Abcam, Cambridge, MA, 1:800, rabbit polyclonal) and
the sections were then incubated with goat anti-rabbit
lgG, dylight™ 594 (America Thermo Fisher, 1:200, goat
anti-rabbit IgG). Sections were counter-stained with
DAPI to identify nuclei before mounting. Then
counter-stained with confocal microscopy.
Measurement of protein expression by western blot analysis
For western blot (WB) analyses, whole aortas were sep-
arately in 200 μl lysis buffer (Tiangen Biotech Co., Ltd.,
China) at 1:100 ratios, adiponectin for total protein, and
NF-κB p65 nuclear fractions were prepared using the
NE-PER Nuclear Protein Extraction kit (Tiangen Biotech
Co., Ltd., China) according to manufacturer’s instruc-
tion. Protein concentrations were assessed with the BCA
protein assay kit (Thermo Scientific, Rockford, IL). Equal
amounts of protein (5 μg) were separated by 7.5 % SDS-
PAGE and transferred to nitrocellulose membranes (Bio-
Rad). Membranes were blocked in 5 % nonfat milk in
PBS with 0.1 % Tween20 or chemiluminescent blocker
(Millipore) at room temperature for 1 h. Expression of
adiponectin, NF-κB p65, and GAPDH protein was
detected by WB analysis with the following primary anti-
bodies at the given dilutions: adiponectin (America
Thermo Fisher, 1:1000), NF-κB p65 antibody (America
Thermo Fisher, 1:100), and GAPDH (Abcam, 1:3000).
They were shaken with primary antibody for 2 h. They
were incubated at 4 °C overnight. After hatching with
1:1000 diluted secondary antibody at 37 °C for 1 h, they
were warm bathed with chemiluminescence reagent ECL
and exposure, developing, and fixing were performed
1 min later. Quantity One software was used for analysis;
the integral optical density value was calculated as the tar-
get protein divided by the internal reference GAPDH pro-
tein. The relative values of protein bands in each group
were expressed as mean ± standard deviation (SD).
Statistical analysis
Statistical analysis was performed with SPSS 22.0 soft-
ware. After the numeric variable data were tested for
Table 1 Sequences of primers for quantitative real-time RT-PCR
Genes Forward Reverse
β-actin 5′- GCTCTTTTCCAGCCTTCCTT -3′ 5′-CTTCTGCATCCTGTCAGCAA-3′
APN 5′- AGGTTGGATGGCAGGC -3′ 5′-TCTCACCCTTAGGACCAAGAA-3′
eNOS 5′- TGTCTGCGGCGATGTCACT -3′ 5′- CATGCCGCCCTCTGTTG -3′
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Fig. 1 (See legend on next page.)
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normality and homogeneity of variance, all parameters
determined in this study are presented as mean ± SD.
The differences among groups were compared using
General Linear Model-Univariate or One-way
ANOVA. P < 0.05 was considered statistically significant
difference.
Results
Overexpression of adiponectin inhibits atherosclerosis in
ApoE-/- mice
The adenovirus mediated overexpression of adiponectin
inhibited the formation of atherosclerotic plaque in
ApoE-/- mice. The surface of atherosclerotic lesion was
decreased significantly (P < 0.001) with the overexpres-
sion of adiponectin: the percentage of surface lesion
in 4 weeks was 27.78 ± 8.64 vs 33.02 ± 5.18 (%);
8 weeks was 31.58 ± 5.87 vs 52.16 ± 5.79 (%), respect-
ively (Fig. 1a, b, c, d, e). The lesion formation in aortic
root in adiponectin group mice was inhibited significantly
(P < 0.01): At 4 week of post-transfection the plaque lesion
areas were 1.50 ± 0.74 × 104 μm2 in control mice vs. 1.35 ±
0.17 × 104 μm2 in adiponectin group mice, and at 8 weeks
the plaque lesion areas were 1.70 ± 0.34 × 104 μm2 in adipo-
nectin group mice vs. 2.21 ± 0.28 × 104 μm2 in control mice;
Fig. 2 Mean lesion area and mean lesion rate of the aortic arch root a HE staining × 200 b The average lesion area of each mouse was determined
from aortic root c The mean lesion rate. Notes: compared with CON group, *P < 0.01; **P < 0.001, n = 6, mean ± SD
(See figure on previous page.)
Fig. 1 Overexpression of adiponectin inhibits atherosclerosis in ApoE-/- mice a Schema of experimental procedure b Lesion areas shown
were quantified using Oil-red O staining of the thoracoabdominal aorta c The overexpression of adiponectin of the aortic arch root by
immunohistochemical approach (×200) d Surface of lesion in thoracoabdominal aorta (%) e the number of APN+ cells/% of total (intimal/medial) area.
Notes: compared with CON group, *P < 0.01, **P < 0.001, n = 6, mean ± SD
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lesion lumen ratios were decreased significantly (P < 0.001):
lesion lumen ratio in 4 weeks was 28.36 ± 3.22 in adiponec-
tin group mice vs 35.61 ± 7.43 (%) in control mice, and
8 weeks was 38.25 ± 6.30 vs 56.89 ± 6.21 (%), respectively
(Fig. 2a, b, c).
Advanced plaques lead to plaque rupture [14]. We
analyzed collagen contents and fibrous cap thickness of
advanced lesions at the level of aortic root. Mice were fed
a high-fat diet for 8 weeks, and histological sections
were examined after Masson trichrome staining. We
Fig. 3 Composition of cells in the aortic arch root a Masson trichrome staining of aortic root (×200) b Collagen content in advanced atherosclerotic
plaques c Fibrous cap thickness. Notes: compared with CON group, *P < 0.01; **P < 0.001, n = 6, mean ± SD
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found a significant increase in collagen content (P < 0.01)
(Fig. 3a, b) and fibrous cap thickness of lesions (P < 0.001)
(Fig. 3a, c) in the adiponectin group mice compared with
control group mice.
Next we examined composition of macrophages (anti-
Mac3) and smooth muscle cells(anti-α-smooth muscle
actin) in the lesions of ApoE-/- mice aortic root (Fig. 4).
Increased macrophage content (P < 0.001) in lesions of
control group mice compared with adiponectin group
mice were detected. In contrast, the relative smooth
muscle cell content was significantly less (P < 0.05) in
the total lesions of control group mice, which represents
the composition of vulnerable plaques.
Overexpression of adiponectin attenuates body weight
increase, hyperlipidemia and MMP-9 level
The adenovirus mediated adiponectin were delivered by
tail vein injection. As shown in Fig. 5a, the expression of
adiponectin in the serum was ≈ 4-fold higher than that
in the control group. The expression of adiponectin
attenuated the increases of serum TC (P < 0.001), TG
(P < 0.001), and LDL-C (P < 0.001) induced by the
Fig. 4 Composition of cells in the aortic arch root a The area of atherosclerotic plaques in sections of the proximal aorta was stained
with an antibody Mac3 against macrophages (×200) b The area of atherosclerotic plaques in sections of the proximal aorta was stained
with an antibody against αSMA (×200) c the number of Mac3+ cells/% of total intimal area d the number of αSMA+ cells/% of total
(intimal/medial) area. Notes: compared with CON group, #P < 0.05; **P < 0.001, n = 6, mean ± SD
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high-fat diet, and attenuated body weight increasing
(P < 0.05) (Table 2). As increasing serum adiponectin,
the level of MMP-9 were significantly decreased (P <
0.05): at 4 week, 50.23 ± 14.24 ng/ml in adiponectin group
vs. 51.33 ± 15.66 ng/ml in control group, and at 8 week,
55.99 ± 11.74 ng/ml vs. 80.50 ± 14.54 ng/ml (Fig. 5b). This
atherosclerosis improvement was found to be due, at least
in part, to downregulation of inflammation state by
increasing serum adiponectin and decreasing MMP-9.
Delivery of adiponectin suppressed the activation of NF-κB
p65, decreased gene and protein expression of
inflammation
Exogenous adiponectin delivery improves inflammation
of atherosclerosis by suppressing the activation of NF-κB
pathway. Adiponectin effectively inhibits the expression
of NF-κB nuclear protein p65. Compared with control
group, expression of adiponectin in aortic root endothe-
lial cells was increased in adiponectin group. Immuno-
fluorescence test suggested that the expression of NF-κB
p65 increased gradually with the prolongation of the
high fat diet time in control group. The expression of
the adiponectin increased and the expression of NF-κB
p65 decreased in the adiponectin group (P < 0.001)
(Figs. 6 and 7).
The exogenous adiponectin increased the mRNA
expression of the anti-inflammatory factors eNOS (P <
0.05) and IL-10 (P < 0.001), and reduced the mRNA
expression of inflammatory factors TNF-α (P < 0.001), IL-
6 (P < 0.001), VCAM-1 (P < 0.05), respectively. Adiponectin
effectively reduced proinflammatory factors gene expres-
sion, indicating that adiponectin can attenuate the inflam-
matory reactions relevant to atherosclerosis (Figs. 8 and 9).
Discussion
Adiponectin deficiency leads to increased oxidative
stress and inflammation under high fat diet conditions
in type 2 diabetic mice [13]. NF-κB has also been
regarded as a proatherogenic factor, mainly because of
its regulation of a variety of the proinflammatory genes
linked to atherosclerosis [15]. Importantly, in current
study, exogenous adiponectin delivery improves inflamma-
tion of atherosclerosis effectively by inhibiting the expres-
sion of NF-κB nuclear protein p65 and proinflammatory
factors regulated by NF-κB. The major findings of the
current work were as follows: 1) Exogenous supplementa-
tion of adiponectin using adenovirus was found to improve
atherosclerosis. 2) This improvement was found to be due,
at least in part, to downregulation of inflammation state by
increasing serum adiponectin and decreasing MMP-9. 3)
Exogenous supplementation of serum protein adiponectin
was found to normalize dyslipidemia by reducing serum
TC, TG, and LDL-C. Mice body weight decreased signifi-
cantly as the adiponectin level increased. 4) Exogenous adi-
ponectin delivery improves inflammation of atherosclerosis
effectively by inhibiting the expression of NF-κB nuclear
protein p65 and inflammatory factors regulated by NF-κB.
Table 2 Mean body weight and TC, TG, LDL-C, HDL-C in serum
Group Body weight (g) TC (mmol/L) TG (mmol/L) LDL-C (mmol/L) HDL-C (mmol/L)
CON 0d 22.79 ± 1.72 7.27 ± 3.51 0.61 ± 0.34 0.79 ± 0.46 0.95 ± 0.41
APN 0d 24.13 ± 3.11 8.01 ± 3.07 0.49 ± 0.24 0.96 ± 0.52 1.38 ± 1.18
CON 4w 27.50 ± 3.31 32.43 ± 10.77 1.18 ± 0.31 10.14 ± 1.48 1.29 ± 0.55
APN 4w 26.04 ± 2.07* 28.66 ± 8.11** 1.03 ± 0.39*** 8.06 ± 1.74*** 0.91 ± 0.33
CON 8w 35.49 ± 3.41 38.12 ± 6.36 2.01 ± 0.77 10.95 ± 3.23 1.86 ± 1.60
APN 8w 29.95 ± 5.53* 24.54 ± 8.29** 1.00 ± 0.30*** 7.57 ± 1.46*** 1.07 ± 0.26
Notes: compared with CON group, *P < 0.05; **P < 0.01; ***P < 0.001, n = 12, mean ± SD
Fig. 5 Level of serum adiponectin、MMP-9 a Serum concentration of adiponectin. b Serum concentration of MMP-9. Notes: compared with CON
group, #P < 0.05; **P < 0.001, n = 12, mean ± SD
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Fig. 6 (See legend on next page.)
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Adiponectin inhibited the formation of atherosclerosis
Atherosclerosis is regarded as an inflammatory disease.
Experimental studies have indicated that adiponectin has
potential anti-atherogenic and anti-inflammatory proper-
ties [16]. In the current study, the formation of athero-
sclerosis plagues was inhibited by adiponectin. The
adiponectin group showed far smaller damaged areas
than those of control group in 4 and 8 weeks. It is sug-
gested that adiponectin prevents and slows the progres-
sion of atherosclerosis. When the vascular endothelium
is injured, adiponectin accumulates in the subintimal
space of the arterial wall through its interaction with
collagens in the vascular intima [17]. Adiponectin inhib-
ited TNF-α-induced monocyte adhesion and expression
of endothelial-leukocyte adhesion molecule-1, E-selectin,
VCAM-1, and ICAM-1 on the endothelium [18]. Previ-
ous studies have shown that elevated plasma adiponectin
suppresses the development of atherosclerosis in vivo
[19]. Fourteen days after Ad-APN treatment, the lesion
formation in aortic sinus was inhibited by 30 % in Ad-
APN treated ApoE-/- mice compared with control mice.
The lipid droplets became smaller than in control mice
[20]. Our previous studies showed that as the dose of
adiponectin increased, atherosclerosis-induced damage
gradually eased [21]. In a recent paper of the Scherer’s
group, genetically manipulated adiponectin levels in
traditional rodent models (adiponectin knockout mice
or mice crossed with the low-density lipoprotein
receptor-null and the apoliprotein E-null mouse models)
did not correlate with a suppression of the atherogenic
process [11]. The lack of a phenotype in gain- and loss
of function study in mice suggests a lack of causation for
adiponectin in inhibiting the buildup of atherosclerotic
lesions [22]. These data indicate that the actions of
adiponectin on the cardiovascular system are complex
and multifaceted. These discrepancies may have been
caused by differences in strain, age, and disease status
among the animals and among the dose and effective
concentration of adiponectin [23].
Overexpression of adiponectin attenuates body weight
increase, hyperlipidemia and MMP-9 level
Lipid accumulation causes dysregulation of adipokine
production, which makes a strong contribution to the
onset of inflammation and atherosclerosis [24]. The
atherogenic process is initiated by the formation of oxi-
dized LDL-cholesterol in the arterial wall, which causes
recruitment of circulating monocytes and differentiation
into macrophages [25]. Clinical studies indicate a close
association of low adiponectin levels with many obesity-
related disorders [26]. Adiponectin which has anti-
hyperglycemic, anti-atherogenic, and anti-inflammatory
properties, could have important clinical benefits in
terms of development of therapies for the prevention
and for the treatment of obesity and obesity-related dis-
eases [27]. In the current study, exogenous adiponectin
supplementation significantly reduced TC,TG, LDL-C
without reducing HDL-C levels. One possible reason for
this is that ApoE, a major apolipoprotein, acts as a ligand
for low-density lipoprotein and very low density lipoprotein
(See figure on previous page.)
Fig. 6 a Nuclear NF-κB p65 expression in the aortic arch root in control group b Nuclear NF-κB p65 expression in the aortic arch root in adiponectin
group c Expression of adiponectin、vWF in the vascular aortas in control group (×200) d Expression of adiponectin、vWF in the vascular aortas in
adiponectin group (×200) e the number of APN+ cells/% of total intimal area f the number of nuclear NF-κB p65+ cells/% of total (intimal/medial) area.
Notes: compared with CON group, *P < 0.01; **P < 0.001, n = 6, mean ± SD
Fig. 7 a Adiponectin protein expression in the aorta b NF-κB p65 protein of nuclear expression in the aorta. Notes: compared with CON group,
**P < 0.001, n = 3, mean ± SD
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receptors in the liver. Atherogenic metabolic disturbances
may not always be adequately reflected by the level of
HDL-C. This was because VLDL contained more choles-
terol and the relative cholesterol content of VLDL in-
creased across TG quintiles [28]. In the current study,
exogenous adiponectin supplementation significantly
reduced body weight gain with HFD feeding. Several lines
of evidence from the metabolomic analyses support the
concept of adiponectin enhancing mitochondrial function.
Adiponectin supplementation induced the coordinated
Fig. 8 Exogenous adiponectin reduces atherosclerosis-induced inflammation in the aorta a mRNA expression of adiponectin in the vascular aortas
of mice b mRNA expression of eNOS c mRNA expression of IL-10 d mRNA expression of VCAM-1 e mRNA expression of TNF-α f mRNA expression
of IL-6. Notes: compared with CON group, *P < 0.01; **P < 0.001, n = 6, mean ± SD
Wang et al. Lipids in Health and Disease  (2016) 15:33 Page 11 of 14
Fig. 9 Exogenous adiponectin reduces atherosclerosis-induced inflammation in the aorta a protein expression of IL-6 in the vascular aortas b protein
expression of TNF-α c protein expression of VCAM-1 d protein expression of IL-10 e protein expression of eNOS. Notes: compared with CON group,
*P < 0.01, n = 3, mean ± SD
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decrease of acetyl-CoA and acylcarnitines and these
occurred with normalization of pathological structures
in the mitochondria [29]. Pair-feeding revealed that
overexpression of globular adiponectin markedly re-
duced body weight gain of ob/ob mice. These data
suggest that overexpression of globular adiponectin
increased energy expenditure and consequently in-
creased food intake [30]. Adiponectin serves as a
regulator of many important hepatic genes in glucose
and lipid biosynthesis and catabolism; the cumulative
effects of all these genes expressed at the optimal
levels create the basal tone essential for maintaining
sensitive insulin responsiveness. For example, in-
creased free fatty acids (FFAs) in plasma induce insu-
lin resistance. Adiponectin promotes the expression of
key hepatic genes in triglyceride formation and lipid
clearance, which promotes FFA clearance from plasma
and to decreased plasma FFAs [31]. MMP-9 is a perfect
biomarker of atherosclerosis. MMP-9 is overexpressed in
progressive atherosclerotic plaques obtained from humans
undergoing endarterectomy and is especially prevalent in
the cap regions where macrophages accumulate, implicat-
ing macrophages and MMP-9 in plaque rupture [32]. The
previous study demonstrated an increased risk of severe
atherosclerosis and unstable plaques in patients with
higher MMP-9 levels [33]. Matrix (ECM) components of
the atherosclerotic plaque, including collagen, elastin, and
proteoglycans, and as such is a critical modulator of
plaque stability [34]. Increased MMP-9 was shown in
advanced atherosclerotic lesions in the Ldl4-/-
Apob100/100 mouse model [35]. In the current study,
there was significantly less expression of MMP-9 in
adiponectin treated group in 8 weeks with the in-
crease of the adiponectin (P < 0.01). This atheroscler-
osis improvement was found to be due, at least in
part, to downregulation of inflammation state by in-
creasing serum adiponectin and decreasing MMP-9.
Delivery of adiponectin suppressed the activation of NF-κB
p65 and proinflammatory gene expression
In current study, exogenous adiponectin increased anti-
inflammatory factor eNOS and IL-10 mRNA expression,
reduced the expression of pro-inflammatory factor TNF-
α, IL-6, VCAM-1 mRNA expression. Adiponectin
effectively inhibited the activation of NF-κB pathway by
inhibiting the expression of NF-κB nuclear protein p65.
NF-κB is a key transcriptional regulator of most inflam-
matory genes and is widely believed to trigger both the
onset and resolution of inflammation by coordinating
the expression of a wide variety of genes that control in-
flammatory and immune responses. Constitutive activa-
tion of NF-κB is often associated with inflammatory
diseases such as rheumatoid arthritis, inflammatory
bowel disease, multiple sclerosis and asthma [36]. In
others vitro study, adiponectin suppressed TNF-α–in-
duced IκBα phosphorylation and subsequent NF-κB acti-
vation without affecting other TNF-α mediated
phosphorylation signals, including Jun N-terminal kinase,
p38 kinase, and Akt kinase. These observations raise the
possibility that adiponectin, which is naturally present in
the blood stream, modulates the inflammatory response of
endothelial cells through cross talk between cAMP-PKA
and NF-κB signaling pathways [37]. Prior work had shown
that adiponectin inhibited endothelial cell dysfunction
through stimulation of endothelial nitric oxide and
endothelium-dependent vasodilation, inhibition of cyto-
kine, chemokine, and adhesion molecule expression [38].
These findings might indicate that, in inflammation, NF-
κB stimulating pathways of adiponectin are likely
suppressed and anti-inflammatory signals are transduced.
Conclusions
To summarize, in current study, it was demonstrated that
adiponectin effectively inhibits the activation of NF-κB
pathway by inhibiting the expression of NF-κB nuclear
protein p65. To elucidate the adiponectin to reduce this
inflammation in atherosclerosis effectively may be in-
volved in inhibiting the NF-κB pathway. In this way, in
addition to the treatment of basic diseases, restoring levels
of adiponectin and the integrity of the vascular tissue by
reducing the inflammation. It may promote pathological
and physiological studies of weight-related diseases and
in-depth studies of the mechanism by which adiponectin
regulates inflammation. Collectively, these findings give
new insights into the linkage between adiponectin and in-
flammation in the course of atherosclerosis, but the most
effective dose of adiponectin has not been identified. The
mechanism by which adiponectin regulates inflammation
is still not very clear. Further studies are needed to evalu-
ate the therapeutic potential of these observations.
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